Latest Anti-angiogenics Stories
This week, the second-year results of an important clinical trial on age-related macular degeneration (AMD), known as the Comparison of AMD Treatments Trials (or CATT), were published in the journal Ophthalmology.
Age-related macular degeneration (AMD) is the leading cause of blindness for people over fifty.
Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
Use of medications injected directly into the eye appears to be an increasingly common treatment for age-related macular degeneration in one region of Canada
WALTHAM, Mass., Feb.
Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
WASHINGTON - What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing.
The National Institute for Health and Clinical Excellence has recommended Novartis's Lucentis as a cost-effective therapy for all eligible patients with wet age-related macular degeneration.
THOUSANDS of people all over the country will be able to receive sightsaving drugs thanks to a campaign spearheaded by three Warwickshire patients. The drug Lucentis will now be available on the NHS to anyone with 'wet' macular degeneration - an eye disease which sends sufferers blind.
- An armed gangster.